NASDAQ: BRVEBraveheart Bio Inc Stock
$20.62-2.75 (-11.77%)
Updated Sep 25, 2026
BRVE Price
$20.62
Fair Value Price
N/A
Market Cap
$1.86B
52 Week Low
$20.53
52 Week High
$32.00
P/E
N/A
P/B
-19.36x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.1
Operating Cash Flow
N/A
Beta
-1.05
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BRVE Overview
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BRVE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BRVE
Ranked#213 of 464
Ranked#213 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.77 | A | |
| $7.75 | A | |
| $360.85 | A |
Be the first to know about important BRVE news, forecast changes, insider trades & much more!
BRVE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BRVE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BRVE's short-term assets ($123.45M) exceed its short-term liabilities ($9.06M)
Short-term Liabilities Financials
BRVE's short-term assets ($123.45M) exceed its long-term liabilities ($284.00k)
Long-term Liabilities Financials
BRVE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more BRVE due diligence checks available for Premium users.
Valuation
BRVE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-19.36x
Industry
5.19x
BRVE's financial health
Profit margin
Revenue
$0.0
Net Income
-$15.0M
Profit Margin
0%
Assets to liabilities
Assets
$127.0M
Liabilities
$9.3M
Debt to equity
-0.1
BRVE's short-term assets ($123.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BRVE's short-term assets ($123.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BRVE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BRVE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.0M
Investing
$8.0k
Financing
$59.2M
BRVE vs Biotech Stocks
Braveheart Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.